RMD 1101
Alternative Names: RMD-1101Latest Information Update: 01 Jan 2024
At a glance
- Originator Remedium Bio
- Class Antirheumatics; Fibroblast growth factors; Gene therapies
- Mechanism of Action Fibroblast growth factor replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 10 Nov 2023 Pharmacodynamics data from a preclinical study in Osteoarthritis presented at ACR Convergence 2023 (ACR-ARP-2023)
- 13 Mar 2023 Pharmacodynamics and adverse events data from a preclinical study in Osteoarthritis released by Remedium Bio
- 01 Oct 2021 Remedium Bio collaborates with Tufts University's Rheumatology laboratory to complete pre-clinical efficacy studies on RMD 1101 for Osteoarthritis